Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-18T19:47:17.033Z Has data issue: false hasContentIssue false

Impact of pharmacist-led microbiology result follow-up post-discharge for patients undergoing inpatient infectious diseases consultation

Published online by Cambridge University Press:  07 August 2024

Amy L. Van Abel*
Affiliation:
Department of Pharmacy, Mayo Clinic, Rochester, MN, USA
Abinash Virk
Affiliation:
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA
Kristin Cole
Affiliation:
Department of Pharmacy, Mayo Clinic, Rochester, MN, USA
Trudi Lane
Affiliation:
Department of Pharmacy, Mayo Clinic, Rochester, MN, USA
Douglas Osmon
Affiliation:
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA
Margaret Pertzborn
Affiliation:
Department of Pharmacy, Mayo Clinic Health System—Northwest Wisconsin Region, Eau Claire, WI, USA
Diana Schreier
Affiliation:
Department of Pharmacy, Mayo Clinic, Rochester, MN, USA
Hilary Teaford
Affiliation:
Department of Pharmacy, Mayo Clinic, Rochester, MN, USA
Courtney Willis
Affiliation:
Department of Pharmacy, Mayo Clinic, Jacksonville, FL, USA
Anna Woods
Affiliation:
Department of Pharmacy, Mayo Clinic, Rochester, MN, USA
Christina G. Rivera
Affiliation:
Department of Pharmacy, Mayo Clinic, Rochester, MN, USA
*
Corresponding author: Amy L. Van Abel; Email: vanabel.amy@mayo.edu

Abstract

Objective:

The primary objective was to determine the rate of clinical actions taken post-discharge on updated microbiology results by an ID pharmacist-led team. Secondary objectives were to describe the microbiology results requiring intervention, characterize interventions by type and severity, and determine time from result to clinical review.

Design:

Retrospective cohort study.

Setting:

Four hospitals within Mayo Clinic, including two large academic centers and two Mayo Clinic Health System sites.

Participants:

Adult patients at four sites within Mayo Clinic from 1/1/2019 to 2/28/2023. Eligible patients had a hospitalization with an ID consult and an updated microbiology result reported after discharge.

Intervention:

Pharmacists reviewed a report of selected patients with microbiology tests that resulted post-discharge within the last 24–96 hours. Interventions were recorded electronically in real-time by the pharmacist. Of those patient encounters with an intervention, a sample of 200 patient encounters was randomly selected for detailed chart abstraction.

Results:

A total of 6,792 encounters with at least one microbiology result reviewed post-discharge were identified. Of these encounters, 1977 (29%) had at least one resulting intervention. Median time from test update to clinical review was 27.2 hours (IQR 21.6–69.6). The highest severity ratings, in which failure to intervene may have resulted in patient harm, were assigned to the intervention in 28% of cases.

Conclusions:

For patients seen by an inpatient ID consult service, a post-hospital discharge microbiology result review process performed by ID-trained pharmacists effectively addressed abnormal results during the transition of care. Similar processes may be considered at other institutions.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Outcome assessment

Figure 1

Table 2.Patient demographics (total cohort)

Figure 2

Table 3.Infection characteristics (focused review subset)

Figure 3

Figure 1.Pharmacist intervention types (n = 200).**Sum >200 due to multiple intervention types per patient encounter.

Figure 4

Table 4.Pharmacist scope of practice by CPA1 summary

Figure 5

Figure 2.Intervention severity (n = 200).

Figure 6

Figure 3.Intervention rates over time in Rochester.**Per year, OR = 0.91, 95% CI, 0.86–0.95, p < 0.001.